Reference is made to the public releases of 24th May 2011 announcing that Valeant Pharmaceuticals International, Inc. (“Valeant”) intends to acquire the entire 87.2% shareholding from the funds advised by Citi Venture Capital International (“CVCI”, through the legal entities Citigroup Venture Capital International Jersey Limited and Baltic Pharma Limited), AB Invalda (“Invalda”), Amber Trust II S.C.A. (“Amber”) and certain other persons (together the “Controlling Shareholders”) and, following such acquisition, to launch a mandatory takeover offer to acquire the remaining shares in AB Sanitas from the minority shareholders (more information is available at: http://www.sanitasgroup.com/index.php/news/news/the-signature-date-of-the-share-sale-and-purchase-agreement-has-been-corrected/11468), and 8th June 2011 regarding the submission of the notification about the proposed transaction to the Competition Council of the Republic of Lithuania (more information is available at: http://www.sanitasgroup.com/announcements/notification-of-the-proposed-transaction-to-competition-authoritires/11478.
Today, on July 22, 2011, AB Sanitas announces that Valeant has received a decision from the Competition Council of the Republic of Lithuania approving Valeant’s intended acquisition without imposing any conditions.
As announced on 11 July 2011, the notification procedure in the Ukraine is also completed (more information is available at: http://www.sanitasgroup.com/announcements/clearance-received-from-the-antimonopoly-committee-of-ukraine-/11529). Clearance from the Polish Office for Competition and Consumer Protection is still pending.
A further announcement will be made when appropriate.
This announcement is also available on AB Sanitas’ website: www.sanitasgroup.com.
A person authorised to provide additional information: Mr. Saulius Jurgelėnas, Chief Executive Officer of AB Sanitas, phone number +370 686 67779.